UNSPSC 51393315: Sulukast

This classification denotes a bronchodilator with the molecular formula C25H36N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M652A5186T, chemically known as 3-(((1r,2e,4z)-1-((alphas)-alpha-hydroxy-m-1h-tetrazol-5-ylbenzyl)-2,4-tetradecadienyl)thio)propionic acid but generally known as sulukast, which bears US NIH Compound Identifier 6436123. European Medicines Agency schedules Sulukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10766MIG.

UNSPSC 51393315 Sulukast (Commodity) covers pharmaceutical and healthcare products state and local governments procure to support emergency response, community health, and pharmacy benefit programs, including naloxone, drug deactivation systems, and direct-to-manufacturer prescription fulfillment capabilities. Recent opportunities show county health departments and state health and human services agencies sourcing naloxone and related overdose-response products through competitive bidding, as well as state agencies exploring pharmacy benefit innovation through direct manufacturer relationships. Issuing bodies span county community health programs and state health and human services commissions, with procurement vehicles ranging from invitation-for-bid (IFB) notices for consumable supplies to requests for information (RFI) for capability assessment and program design.

Seminole County, Florida posted IFB60459723LAS on June 30, 2026, seeking to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to solicit vendor information on direct-to-manufacturer prescription programs and direct contracting capabilities outside traditional pharmacy benefit manager and wholesaler arrangements, with response deadline April 3, 2026. Geographic activity centers on Florida and Texas, with the Seminole County solicitation emphasizing consumable procurement for community health infrastructure and the Texas HHS Commission signaling state-level interest in pharmacy benefit restructuring through direct manufacturer relationships.